Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study

Albert Y Liu, Eric Vittinghoff, Patricia von Felten, K Rivet Amico, Peter L Anderson, Richard Lester, Erin Andrew, Ixchell Estes, Pedro Serrano, Jennifer Brothers, Susan Buchbinder, Sybil Hosek, Jonathan D Fuchs, Albert Y Liu, Eric Vittinghoff, Patricia von Felten, K Rivet Amico, Peter L Anderson, Richard Lester, Erin Andrew, Ixchell Estes, Pedro Serrano, Jennifer Brothers, Susan Buchbinder, Sybil Hosek, Jonathan D Fuchs

Abstract

Background: Young men who have sex with men are among the most vulnerable to human immunodeficiency virus (HIV) infection. Although preexposure prophylaxis (PrEP) has demonstrated effectiveness, adherence and retention have been low among youth.

Methods: We conducted a randomized controlled trial to evaluate the impact of a youth-tailored, bidirectional text-messaging intervention (PrEPmate) on study retention and PrEP adherence. Young individuals at risk for HIV initiating PrEP within Chicago's safety-net system were randomized 2:1 to receive PrEPmate or standard of care (SoC) for 36 weeks. The primary retention outcome was study-visit completion, and the primary adherence outcome was tenofovir diphosphate (TFV-DP) concentrations ≥700 fmol/punch (consistent with ≥4 doses/week) assessed at 4, 12, 24, and 36 weeks. The impact of PrEPmate on retention and adherence was evaluated using generalized estimating equation logistic models with robust standard errors.

Results: From April 2015 to March 2016, 121 participants enrolled (mean age 24; 27% black, 36% Latino). Participants who received PrEPmate were more likely to attend study visits (86% PrEPmate vs. 71% SoC, odds ratio [OR] = 2.62, 95% confidence interval [CI] 1.24-5.54) and have TFV-DP levels consistent with ≥4 doses/week (72% PrEPmate vs. 57% SoC, OR = 2.05, 95% CI 1.06-3.94). PrEPmate efficacy did not differ significantly by age, race/ethnicity, education, or insurance. Overall, 88% reported PrEPmate to be very/somewhat helpful, and 92% would recommend PrEPmate to others.

Conclusions: An interactive text-messaging intervention had high acceptability and significantly increased study-visit retention and PrEP adherence among young individuals at risk for HIV acquisition.

Clinical trials registration: NCT02371525.

Keywords: adherence; men who have sex with men (MSM); preexposure prophylaxis (PrEP); retention; text-messaging.

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Consort diagram.
Figure 2.
Figure 2.
Overall retention and adherence based on tenofovir diphosphate concentrations, by visit week. At wks 4, 12, and 24, 3–4 participants were seen for the visit but did not have dried blood spots collected. Abbreviations: BLQ, below the limit of quantitation; Wk, study week.
Figure 3.
Figure 3.
Visit retention by study arm.
Figure 4.
Figure 4.
Adherence by tenofovir diphosphate, by study arm and visit week.

References

    1. Grant RM, Lama JR, Anderson PL, et al. ; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587–99.
    1. Baeten JM, Donnell D, Ndase P, et al. ; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399–410.
    1. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. ; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423–34.
    1. Choopanya K, Martin M, Suntharasamai P, et al. ; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381:2083–90.
    1. Molina JM, Capitant C, Spire B, et al. ; ANRS IPERGAY Study Group. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015; 373:2237–46.
    1. Grant RM, Anderson PL, McMahan V, et al. ; iPrEx study team. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014; 14:820–9.
    1. McCormack S, Dunn DT, Desai M, et al. . Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016; 387:53–60.
    1. Liu AY, Cohen SE, Vittinghoff E, et al. . Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med 2016; 176:75–84.
    1. Marcus JL, Hurley LB, Hare CB, et al. . Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation. J Acquir Immune Defic Syndr 2016; 73:540–6.
    1. Van Damme L, Corneli A, Ahmed K, et al. ; FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411–22.
    1. Marrazzo JM, Ramjee G, Richardson BA, et al. ; VOICE Study Team. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015; 372:509–18.
    1. Chan PA, Mena L, Patel R, et al. . Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. J Int AIDS Soc 2016; 19:20903.
    1. Hojilla JC, Vlahov D, Crouch PC, Dawson-Rose C, Freeborn K, Carrico A. HIV Pre-exposure prophylaxis (PrEP) uptake and retention among men who have sex with men in a community-based sexual health clinic. AIDS Behav 2018; 22:1096–9.
    1. Jenness SM, Goodreau SM, Rosenberg E, et al. . Impact of the centers for disease control’s HIV preexposure prophylaxis guidelines for men who have sex with men in the United States. J Infect Dis 2016; 214:1800–7.
    1. HIV Among Youth Available at: . Accessed 14 May 2018.
    1. Singh S, Song R, Johnson AS, McCray E, Hall HI. HIV incidence, prevalence, and undiagnosed infections in U.S. men who have sex with men. Ann Intern Med 2018; 168:685–94.
    1. Mera Giler R, Magnuson D, Trevor H, Bush S, Rawlings K, McCallister S. Changes in Truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States: (2012–2016). In: 2017 International AIDS Society Meeting; 23–26 July 2017; Paris, France.
    1. Morgan E, Ryan DT, Newcomb ME, Mustanski B. High rate of discontinuation may diminish PrEP coverage among young men who have sex with men. AIDS Behav 2018.
    1. Hosek SG, Rudy B, Landovitz R, et al. ; Adolescent Trials Network (ATN) for HIVAIDS Interventions. An HIV preexposure prophylaxis demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr 2017; 74:21–9.
    1. Hosek SG, Landovitz RJ, Kapogiannis B, et al. . Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States. JAMA Pediatr 2017; 171:1063–71.
    1. Lester RT, Ritvo P, Mills EJ, et al. . Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 2010; 376:1838–45.
    1. Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. . Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS 2011; 25:825–34.
    1. Mayer JE, Fontelo P. Meta-analysis on the effect of text message reminders for HIV-related compliance. AIDS Care 2017; 29:409–17.
    1. Finitsis DJ, Pellowski JA, Johnson BT. Text message intervention designs to promote adherence to antiretroviral therapy (ART): a meta-analysis of randomized controlled trials. PLoS One 2014; 9:e88166.
    1. Moore DJ, Jain S, Dubé MP, et al. . Randomized controlled trial of daily text messages to support adherence to preexposure prophylaxis in individuals at risk for human immunodeficiency virus: the TAPIR study. Clin Infect Dis 2018; 66:1566–72.
    1. Khosropour CM, Lester RT, Golden MR, Dombrowski JC. Text messaging is associated with improved retention in a clinic-based PrEP program. In: Conference on Retroviruses and Opportunistic Infections; 4–7 March 2018; Boston, MA.
    1. Gold J, Lim MS, Hocking JS, Keogh LA, Spelman T, Hellard ME. Determining the impact of text messaging for sexual health promotion to young people. Sex Transm Dis 2011; 38:247–52.
    1. Muessig KE, Pike EC, Fowler B, et al. . Putting prevention in their pockets: developing mobile phone-based HIV interventions for black men who have sex with men. AIDS Patient Care STDS 2013; 27:211–22.
    1. Mobile fact sheet Available at:. Accessed 14 May 2018.
    1. Fuchs JD, Stojanovski K, Vittinghoff E, et al. . A mobile health strategy to support adherence to antiretroviral preexposure prophylaxis. AIDS Patient Care STDS 2018; 32:104–11.
    1. Chicago Department of Public Health. HIV/STI surveillance report 2017. Chicago, IL: City of Chicago, 2017.
    1. Olson-Kennedy J, Cohen-Kettenis PT, Kreukels BP, et al. . Research priorities for gender nonconforming/transgender youth: gender identity development and biopsychosocial outcomes. Curr Opin Endocrinol Diabetes Obes 2016; 23:172–9.
    1. What is PrEP? Available at: . Accessed 14 May 2018.
    1. Liu A, Vittinghoff E, von Felten P, et al. . SMS support increases PrEP retention and adherence among young MSM and transgender women in Chicago. 12th International Conference on HIV treatment and prevention adherence; 4-6 June. 2017; Miami, FL.
    1. Fisher JD, Amico KR, Fisher WA, Harman JJ. The information-motivation-behavioral skills model of antiretroviral adherence and its applications. Curr HIV/AIDS Rep 2008; 5:193–203.
    1. Liu A, Cohen S, Follansbee S, et al. . Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med 2014; 11:e1001613.
    1. Smillie K, Van Borek N, Abaki J, et al. . A qualitative study investigating the use of a mobile phone short message service designed to improve HIV adherence and retention in care in Canada (WelTel BC1). J Assoc Nurses AIDS Care 2014; 25:614–25.
    1. Chiang N, Guo M, Amico KR, Atkins L, Lester RT. Interactive two-way mHealth interventions for improving medication adherence: an evaluation using the behaviour change wheel framework. JMIR Mhealth Uhealth 2018; 6:e87.
    1. Holloway IW, Dougherty R, Gildner J, et al. . Brief report: PrEP uptake, adherence, and discontinuation among California YMSM using geosocial networking applications. J Acquir Immune Defic Syndr 2017; 74:15–20.
    1. Whitfield THF, John SA, Rendina HJ, Grov C, Parsons JT. Why I quit pre-exposure prophylaxis (PrEP)? A mixed-method study exploring reasons for prep discontinuation and potential re-initiation among gay and bisexual men. AIDS Behav 2018. Epub ahead of print.
    1. Bardosh KL, Murray M, Khaemba AM, Smillie K, Lester R. Operationalizing mHealth to improve patient care: a qualitative implementation science evaluation of the WelTel texting intervention in Canada and Kenya. Global Health 2017; 13:87.
    1. Gilead Sciences. Press release: US Food and Drug Administration approves expanded indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for reducing the risk of acquiring HIV-1 in adolescents. Foster City, CA, 2018. Available at:

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren